Gilead Sciences is building up its autoimmune disease drug pipeline by turning to EVOQ Therapeutics, a startup with technology that takes a novel approach to restoring immune tolerance. For EVOQ, the Gilead deal is its second with a big pharma company.
The FDA approved Nexlizet, according to an entry in its database of approved drugs. The new drug combines the active ingredient of Nexletol - which the FDA approved last week - with a generic non-statin drug, ezetimibe.
The drug, Nexletol, is designed for use with maximally tolerated statins for lowering LDL cholesterol in patients with heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease.
The new fund is the single largest ever raised in Michigan eclipsing the earlier $220 million Arboretum IV fund raised in 2015.
The Ann Arbor, Michigan-based startup intends to use the funding to secure FDA clearance of its first product, which works to detect the emergence of hemodynamic instability.
A study published in JAMA suggests that administrative data could be a more timely and accurate way to assess the effectiveness of devices like the gastric band.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
"We are patients as designers, reinventing a system we have intimate experience with from the ground up," said Workit Health Co-founder Robin McIntosh.
Engineering researchers at the University of Michigan have developed a battery-operated injectable computer with a radio antenna that can transmit data to a device located up to 12 inches outside of the body.
The Michigan researchers developed a microfluidic device that sandwiches a thin, permeable polyester membrane and a layer of cultured kidney cells between the top and bottom compartments.
RetroSense Therapeutics, an Ann Arbor optogenetics startup, is developing an algae-based gene therapy that could restore functional sight in those with congenital vision loss disorders.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Richard A. Correll, who helped establish and promote the job of the healthcare CIO and who later co-founded the College of Healthcare Information Management Executives (CHIME) will retire June 30 after 42 years in the health IT industry.
The appetite for health data grows and along with it conversations on people’s comfort level with making that information available. Young people tend to have a pretty passive attitude towards their health data being shared compared with older folks. But for those willing to share it, who are they most likely to trust with it? […]
When Dr. Joyce Lee, a pediatric endocrinologist and associate professor of pediatrics at the University of Michigan Medical School, talks about the origins of a patient-centered participatory design initiative in the Ann Arbor community, it begins with her son. She temporarily relocated her family to California as part of a sabbatical, and developed a series […]
A Michigan startup is using 3D printing technology to help surgeons reconstruct skeletal defects – minimizing the need for bone grafts to fill areas with significant missing bone. Tissue Regeneration Systems is developing porous, bioresorbable scaffolding that can replace itself with natural bone, leaving no residual implanted device. Instead of requiring metal plates and screws, the material is computer […]
In its second wind as a company, Esperion Therapeutics (once owned by Pfizer) has just collected $33 million to continue with clinical trials of its cholesterol-lowering drug. Plymouth, Michigan-based Esperion is in phase 2 trials of ETC-1002, a once-daily oral drug designed to regulate abnormal lipid and carbohydrate metabolism without many of the side effects […]
